Biblio

48 resultats trouvés
Filtres: Auteur is Tiberghien, Pierre  [Clear All Filters]
A
Garraud O, Lacombe K, Tiberghien P.  2021.  A look-back at convalescent plasma to treat COVID-19. TRANSFUSION AND APHERESIS SCIENCE. 60:103063.
Mansuy JMichel, Gallian P, Dimeglio C, Saune K, Arnaud C, Pelletier B, Morel P, Legrand D, Tiberghien P, Izopet J.  2016.  A Nationwide Survey of Hepatitis E Viral Infection in French Blood Donors. HEPATOLOGY. 63:1145-1154.
Lacroix J, Hebert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L, Callum J, Turgeon AF et al..  2015.  Age of Transfused Blood in Critically Ill Adults. NEW ENGLAND JOURNAL OF MEDICINE. 372:1410-1418.
Ducloux D, Gaiffe E, Vernerey D, Bardiaux L, Leroux F, Meurisse A, Courivaud C, Bamoulid J, Saas P, Tiberghien P.  2019.  ASSOCIATION BETWEEN AGE OF RED BLOOD CELL FOR TRANSFUSION AND OUTCOMES AFTER KIDNEY TRANSPLANTATION: A LONGITUDINAL NATIONWIDE ANALYSIS. TRANSPLANT INTERNATIONAL. 32:14-15.
Ducloux D, Gaiffe E, Vernerey D, Bardiaux L, Leroux F, Meurisse A, Courivaud C, Bamoulid J, Saas P, Tiberghien P.  2019.  ASSOCIATION BETWEEN AGE OF RED BLOOD CELL FOR TRANSFUSION AND OUTCOMES AFTER KIDNEY TRANSPLANTATION: A LONGITUDINAL NATIONWIDE ANALYSIS. TRANSPLANT INTERNATIONAL. 32:14-15.
B
Tiberghien P.  2019.  The best blood product and its best use for each patient: An evolving role for hemovigilance? TRANSFUSION CLINIQUE ET BIOLOGIQUE. 26:188-191.
Follea G, Garraud O, Tiberghien P.  2015.  Blood transfusion: The challenges for tomorrow? PRESSE MEDICALE. 44:227-232.
Garraud O, Morel P, Coste J, Tiberghien P, Fournier-Wirth C.  2015.  Blood transfusion - the value of Research and Development programs. PRESSE MEDICALE. 44:233-240.
C
Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y.  2020.  Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? VOX SANGUINIS. 115:488-494.
Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y.  2020.  Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? VOX SANGUINIS. 115:488-494.
Gallian P, Couchouron A, Dupont I, Fabra C, Piquet Y, Djoudi R, Assal A, Tiberghien P.  2017.  Comparison of hepatitis E virus nucleic acid test screening platforms and RNA prevalence in French blood donors. TRANSFUSION. 57:223-224.
Garban F, Guyard A, Labussiere H, Bulabois C-E, Marchand T, Mounier C, Caillot D, Bay J-O, Coiteux V, Schmidt-Tanguy A et al..  2018.  Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases A Randomized Clinical Trial. JAMA ONCOLOGY. 4:468-475.
Hueso T, Pouderoux C, Pere H, Beaumont A-L, Raillon L-A, Ader F, Chatenoud L, Eshagh D, Szwebel T-A, Martinot M et al..  2020.  Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. BLOOD. 136:2290-2295.
Tiberghien P, Toussirot E, Richard P, Morel P, Garraud O.  2021.  Convalescent plasma to treat COVID-19: Following the Argentinian lead. TRANSFUSION AND APHERESIS SCIENCE. 60:103161.
Gallian P, Le Cam S, Brisbarre N, Pastorino B, Amroun A, Malard L, de Lamballerie X, Bliem C, Richard P, Morel P et al..  Submitted.  COVID-19 convalescent plasma: Evolving strategies for serological screening in France. VOX SANGUINIS.
D
Bougard D, Brandel J-P, Belondrade M, Beringue V, Segarra C, Fleury H, Laplanche J-L, Mayran C, Nicot S, Green A et al..  2016.  Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. SCIENCE TRANSLATIONAL MEDICINE. 8:370ra182.
Zuber J, Boyer O, Neven B, Jollet I, Renac V, Berthaud R, Levy R, Lamarthee B, Visentin J, Marchal A et al..  2020.  Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation. AMERICAN JOURNAL OF TRANSPLANTATION. 20:2243-2253.
E
Desmarets M, Bardiaux L, Benzenine E, Dussaucy A, Binda D, Tiberghien P, Quantin C, Monnet E.  2016.  Effect of storage time and donor sex of transfused red blood cells on 1-year survival in patients undergoing cardiac surgery: an observational study. TRANSFUSION. 56:1213-1222.
Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys HB, van Der Schoot E.  Submitted.  Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. VOX SANGUINIS.
Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys HB, van Der Schoot E.  2021.  Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. VOX SANGUINIS. 116:493-496.
H
Gallian P, Barlet V, Mouna L, Gross S, Lecam S, Ricard C, Wind F, Pouchol E, Fabra C, Flan B et al..  2018.  Hepatitis A: an epidemiological survey in blood donors, France 2015 to 2017. EUROSURVEILLANCE. 23:1800237.
Hauser L, Roque-Afonso A-M, Beyloune A, Simonet M, Fischer BDeau, Roziers NBurin des, Mallet V, Tiberghien P, Bierling P.  2014.  Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. BLOOD. 123:796-797.
Gallian P, Lhomme S, Piquet Y, Saune K, Abravanel F, Assal A, Tiberghien P, Izopet J.  2014.  Hepatitis E Virus Infections in Blood Donors, France. EMERGING INFECTIOUS DISEASES. 20:1914-1917.
Cappy P, Chaillon A, Pillonel J, Essat A, Chaix M-L, Meyer L, Barin F, Tiberghien P, Laperche S.  2021.  HIV transmission network analysis allows identifying unreported risk factors in HIV-positive blood donors in France. TRANSFUSION. 61:1191-1201.
Cappy P, Chaillon A, Pillonel J, Essat A, Chaix M-L, Meyer L, Barin F, Tiberghien P, Laperche S.  Submitted.  HIV transmission network analysis allows identifying unreported risk factors in HIV-positive blood donors in France. TRANSFUSION.

Pages